EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA

Wenxue Bai, Mengyao Guo iD, Lijuan Hua, Xuezhao Wang, Lirong Chen iD, Bingyi Liu iD, Yi Wang, Ying Zhou, Qi Wang, Ni Zhang, Lan Chen, Min Wu und 2 weitere

Therapeutic Advances in Respiratory Disease · 2026-05 · 20

DOI: 10.1177/17534666261451630 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 28.05.2026. Verfasst von Wenxue Bai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, …. Hauptthemen laut MEDLINE: Birt-Hogg-Dube Syndrome, RNA, Messenger, Tumor Suppressor Proteins, Proto-Oncogene Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder caused by folliculin ( FLCN ) gene mutations, with ethnically heterogeneous mutational spectra. Current management is primarily supportive and lacks curative therapies.

Objectives

This study aimed to characterize the clinical features and genetic variants in two distinct Chinese families with BHD syndrome and to preliminarily explore the feasibility of an mRNA-based protein replacement approach.

Design

A family-based prospective cohort study was conducted to identify FLCN mutations in two BHD families carrying rare FLCN variants enrolled in 2023.

Methods

Whole-exome sequencing (WES) identified candidate mutations in probands, which were validated by Sanger sequencing (p.W376R and p.Q44*). Structural/functional impacts of p.W376R were analyzed via bioinformatics and qPCR. HEK293T cells were transfected with empty vector, wild-type FLCN , or mutant plasmids (p.W376R and p.Q44*), followed by co-transfection with or without synthetic FLCN mRNA. FLCN expression and mTORC1 signaling were assessed.

Results

Affected members in both families predominantly presented with respiratory symptoms, lacking typical skin lesions and kidney tumors. WES identified the FLCN variants p.W376R (previously classified as a Variant of Uncertain Significance, VUS) and a novel nonsense mutation p.Q44*. Genotype–phenotype co-segregation was confirmed for p.W376R. In vitro analyses demonstrated that both mutations reduced FLCN protein expression, leading to mTORC1 hyperactivation. Exogenous FLCN mRNA delivery rescued functional protein expression and reversed mTORC1 dysregulation.

Conclusion

We provide co-segregation and functional evidence supporting the reclassification of the FLCN p.W376R variant as pathogenic according to ACMG guidelines and report a novel pathogenic mutation, p.Q44*, expanding the known FLCN mutational spectrum. Importantly, FLCN mRNA supplementation restored FLCN expression in vitro, providing preliminary evidence for mRNA-based therapeutic strategies in BHD syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Birt-Hogg-Dube SyndromeRNA, MessengerTumor Suppressor ProteinsProto-Oncogene ProteinsMutationHumansPedigreeHEK293 CellsFemaleMaleProspective StudiesExome SequencingPhenotypeMechanistic Target of Rapamycin Complex 1AdultTransfection

Stichwörter der Autor:innen

BHD syndromeFLCNmRNA interventionp.Q44*p.W376R

Substanzen

FLCN protein, humanRNA, MessengerTumor Suppressor ProteinsProto-Oncogene ProteinsMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
  • Division of Cardiology, Departments of Internal Medicine and Genetic Diagnosis Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

ORCID-Profile: Mengyao Guo, Lirong Chen, Bingyi Liu, Min Xie

Zitieren

APA

Bai, W., Guo, M., Hua, L., Wang, X., Chen, L., Liu, B., Wang, Y., Zhou, Y., Wang, Q., Zhang, N., Chen, L., Wu, M., Li, Z., & Xie, M. (2026). Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261451630

Vancouver

Bai W, Guo M, Hua L, Wang X, Chen L, Liu B, et al. Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261451630

BibTeX
@article{Bai2026,
  author = {Bai, Wenxue and Guo, Mengyao and Hua, Lijuan and Wang, Xuezhao and Chen, Lirong and Liu, Bingyi and Wang, Yi and Zhou, Ying and Wang, Qi and Zhang, Ni and Chen, Lan and Wu, Min and Li, Zongzhe and Xie, Min},
  title = {Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261451630}
}
Kostenlos starten →